Antibody Ingredients TRIZ Cases

Fully human anti-human CD226 agonist antibodies resolve species incompatibility by stimulating T cell-derived IFNγ production to inhibit solid tumor growth.

Anti-Notch2 antibodies target secretory cells to reduce mucus production in lungs.

Anti-NKG2A antibodies bind NKG2A receptors to block inhibitory signals, restoring NK and T cell cytotoxic activity against cancer cells.

A SpatialScore ratio derived from effector immune cell distances predicts patient response to immunotherapy.

A novel cyclic carbonyl linker prevents retro-Michael reactions in ROR1 antibody-drug conjugates, maintaining drug stability and reducing systemic toxicity.

Monoclonal antibodies bind 14-3-3 epsilon proteins on irradiated tumor cells to enable targeted drug delivery.

Heat treatment of intact cell pellets precipitates host proteins, resolving the trade-off between purification efficiency and production time.

Targeting annexin-A1 reverses platinum-based chemotherapy resistance, restoring treatment efficacy across multiple resistant cancer types.

Anti-CD276 antibody-drug conjugate delivers chemotherapy to tumor cells while activating NK and T immune responses against triple-negative breast cancer.

Multivalent meditopes cluster surface antigens for rapid internalization, reducing off-target effects and circulation time.

Humanized antibody frameworks reduce immunogenic rejection while preserving antigen binding for effective non-small cell lung cancer treatment.

Antibodies targeting the beta subunit of Na+K+-ATPase prevent thrombosis by blocking platelet aggregation pathways that conventional treatments fail to address.

Bispecific antibodies targeting ILT4 and PD-L1 simultaneously block immune evasion pathways, enhancing anti-tumor responses.

A monoclonal antibody binds specific EL regions to inhibit enzyme activity, resolving polyclonal immunogenicity while maintaining therapeutic efficacy.

Escalating monoclonal antibody doses suppress allergic reactions without allergen risks.

Modifying glycosylation on the Fc region enhances ADCC activity, selectively depleting regulatory T cells while preserving anti-tumor CD8+ T cells.

Glycoengineered antibodies reduce fucosylation to boost ADCC activity, resolving cross-reactivity with soluble CEA that limits cancer treatment efficacy.

Optimized antibody variable regions inhibit soluble CD73 activity and reverse T cell suppression for enhanced tumor treatment.

Grafting murine CDRs into a human framework with backmutations resolves aggregation and boosts expression levels in non-mammalian systems.

Integrin ligand mimetics boost immune response to antigens while avoiding side effects from conventional adjuvants like alum.

Anti-TMEM-180 antibody targets transmembrane protein 180 on colon cancer cells, sparing normal tissue from adverse effects.

Targeted amino acid substitutions in the heavy chain CDR2 domain reduce deamidation susceptibility while maintaining high binding affinity to human LAG-3.

Optimizing aluminum adjuvant concentration stabilizes the formulation against thermal degradation, reducing cold storage requirements.

Single domain antibodies disrupt tumor vascularization by blocking IGFBP7 binding to CD93 in hypoxic solid tumors.

Targeted monoclonal antibodies inhibit IL-4 and IL-13 signaling via IL-4Rα binding, reducing inflammation in atopic dermatitis and asthma.

Engineered monoclonal antibodies sequester (+)methamphetamine in the bloodstream, preventing brain accumulation while avoiding cross-reactivity with (-)isomers.

Humanized antibodies targeting prostate stem cell antigen reduce immunogenicity while maintaining binding affinity.

Anti-CCR8 antibodies deplete tumor-infiltrating regulatory T cells via enhanced antibody-dependent cell-mediated cytotoxicity.

Reducing fucose content at Asn297 in afucosylated anti-CD20 antibodies resolves suboptimal synergistic effects when combined with Bcl-2 and MDM2 inhibitors.

An anti-TM4SF20 monoclonal antibody binds to TM4SF20 proteins on cancer cells to induce cell death through cytotoxic mechanisms.

Combines a reversible BTK inhibitor with an immune checkpoint antibody to produce synergistic anticancer action.

Segmented nanoparticles and antibody carriers penetrate solid tumors while minimizing systemic toxicity.

A recombinant artificial polyclonal immunoglobulin composition uses multiple single chain variable fragments to deliver therapeutic effects.

Addresses ineffective chemotherapy in microsatellite stable colorectal cancer by blocking inhibitory receptors to restore immune recognition.

Unequal Fc chains prevent homodimer formation in asymmetric bispecific antibodies, extending half-life while avoiding effector cell mutual killing.

TMPRSS2 inhibitors block hemagglutinin cleavage, reducing influenza viral burden and infection symptoms.

Isoform-specific antibody molecules bind selectively to oncogenic FGFR2 variants to inhibit cancer cell proliferation and angiogenesis.

Fully human anti-PD-1 antibodies bind PD-1 with high affinity to block tumor immune suppression.